Ganciclovir

Generic Name: Ganciclovir

Brand Names: Cytovene, Zirgan

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₅O_₄

CAS Number: 82410-32-0

Unique Ingredient Identifier: P9G3CKZ4P5

Background: An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

Indication: For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.

Associated Conditions: CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Roche Global Development

Target Recruit Count: 280

Registration Number: NCT00002330

Locations: 🇺🇸
Dr Ken Fisher, Phoenix, Arizona, United States
🇺🇸
Dr Daniel Barbero, Fort Worth, Texas, United States
🇺🇸
Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States

and more 33 locations

Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient

Not Applicable

Completed

Conditions: Cytomegalovirus Infections
Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00002025

Locations: 🇺🇸
Roche Global Development - Palo Alto, Palo Alto, California, United States

A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine

Phase 1

Completed

Conditions: Cytomegalovirus Infections
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT00002096

Locations: 🇺🇸
Georgetown Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸
Ctr for Special Immunology, Irvine, California, United States
🇺🇸
Univ TX Galveston Med Branch, Galveston, Texas, United States

A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Roche Global Development

Target Recruit Count: 450

Registration Number: NCT00002134

Locations: 🇺🇸
Saint Clare's Prof Office, New York, New York, United States
🇺🇸
Dr Neil Brourman, Beverly Hills, California, United States
🇺🇸
Santa Clara Valley Med Ctr, San Jose, California, United States

and more 20 locations

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

Phase 3

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2017-05-17

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT00002377

Locations: 🇺🇸
Univ of California / San Diego / Dept of Pediatrics, La Jolla, California, United States
🇺🇸
St Luke's - Roosevelt Hosp Ctr / Div of Infect Dis, New York, New York, United States
🇺🇸
New York Hosp - Cornell Med Ctr, New York, New York, United States

and more 16 locations

A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: American National Red Cross

Registration Number: NCT00001999

Locations: 🇺🇸
Georgetown Univ Med Ctr, Washington, District of Columbia, United States

Islet Transplantation for Type 1 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Insulin-Dependent

Interventions: Procedure: Islet Transplantation
Drug: Sirolimus
Drug: Tacrolimus
Drug: Daclizumab
Drug: Sulfamethoxazole
Drug: Ganciclovir
Drug: Trimethoprim
Drug: Pentamidine

First Posted Date: 2001-08-31

Last Posted Date: 2017-03-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00014911

Locations: 🇩🇪
Justus-Leibig University, Giessen, Germany
🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇭
University of Geneva, Geneva, Switzerland

and more 6 locations

A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

Phase 1

Completed

Conditions: HIV Infections
Colitis

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00000768

Locations: 🇺🇸
Alabama Therapeutics CRS, Birmingham, Alabama, United States
🇺🇸
Washington U CRS, Saint Louis, Missouri, United States
🇺🇸
Univ. of Cincinnati CRS, Cincinnati, Ohio, United States

and more 2 locations

A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir

Phase 1

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT00000970

Locations: 🇺🇸
Ucsf Aids Crs, San Francisco, California, United States
🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸
Washington U CRS, Saint Louis, Missouri, United States

and more 3 locations

A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection

Not Applicable

Completed

Conditions: Cytomegalovirus Infections
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00000995

Locations: 🇺🇸
Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸
Univ of Rochester Medical Center, Rochester, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy